Published in Cancer Epidemiol Biomarkers Prev on February 01, 2002
Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol Aspects Med (2008) 1.56
Buccal micronucleus cytome assay. Nat Protoc (2009) 1.36
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci (2011) 1.35
N-acetylcysteine -- passe-partout or much ado about nothing? Br J Clin Pharmacol (2006) 1.23
Oral microbiota and cancer. J Oral Microbiol (2010) 1.18
Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev Res (Phila) (2010) 1.13
Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol (2012) 1.10
Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs (2014) 1.04
Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis (2008) 1.03
Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta (2011) 0.99
Antioxidant therapies in COPD. Int J Chron Obstruct Pulmon Dis (2006) 0.91
A role for fibroblasts in mediating the effects of tobacco-induced epithelial cell growth and invasion. Mol Cancer Res (2008) 0.91
Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis (2007) 0.89
Micronucleus analysis in patients with colorectal adenocarcinoma and colorectal polyps. World J Gastroenterol (2008) 0.87
Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food Chem Toxicol (2007) 0.84
Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol (2008) 0.81
Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. CNS Neurol Disord Drug Targets (2015) 0.80
Micronucleus investigation in human buccal epithelial cells of gutkha users. Adv Biomed Res (2012) 0.79
Micronuclei levels in peripheral blood lymphocytes as a potential biomarker for pancreatic cancer risk. Carcinogenesis (2010) 0.78
Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence. Trends Pharmacol Sci (2015) 0.77
N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med (2016) 0.76
Translational toxicology: a developmental focus for integrated research strategies. BMC Pharmacol Toxicol (2013) 0.76
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav (2016) 0.75
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Mutations induced by ultraviolet light. Mutat Res (2005) 4.45
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys (2004) 3.40
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol (2006) 2.81
Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol (2008) 2.78
Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med (2003) 2.75
Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J (2008) 2.58
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. Cancer (2010) 2.40
Mutational spectra of human cancer. Hum Genet (2009) 2.26
Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol (2005) 2.13
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Hormesis in precautionary regulatory culture: models preferences and the advancement of science. Hum Exp Toxicol (2007) 2.05
Photodynamic therapy in oncology. Oncologist (2006) 2.04
The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats. J Surg Oncol (2012) 2.03
Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol (2002) 1.79
Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol (2008) 1.73
Glaucomatous outflow pathway and oxidative stress. Exp Eye Res (2006) 1.71
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.70
Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.67
The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol (2007) 1.62
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol (2013) 1.59
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood (2009) 1.57
Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med (2012) 1.53
UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci (2011) 1.51
Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J (2002) 1.51
Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment. J Thorac Oncol (2009) 1.41
Genotoxic damage in the oral mucosa cells of subjects carrying restorative dental fillings. Arch Toxicol (2012) 1.39
Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J (2009) 1.31
Increased carotid wall thickening after radiotherapy on the neck. Eur J Cancer (2005) 1.25
Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol (2011) 1.25
Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr (2008) 1.23
Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol (2002) 1.22
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
ATP-mediated activation of the NADPH oxidase DUOX1 mediates airway epithelial responses to bacterial stimuli. J Biol Chem (2009) 1.21
Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep (2010) 1.18
Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res (2005) 1.17
Potent carcinogenicity of cigarette smoke in mice exposed early in life. Carcinogenesis (2007) 1.17
MicroRNAs in cancer treatment and prognosis. Am J Cancer Res (2012) 1.17
The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochem Biophys Res Commun (2002) 1.17
Erythritol is a sweet antioxidant. Nutrition (2009) 1.17
Telomere shortening in chronic obstructive pulmonary disease. Respir Med (2008) 1.16
Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr (2010) 1.16
Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.16
Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-(99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging (2012) 1.15
First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol (2003) 1.14
Biomarkers. Mol Aspects Med (2002) 1.14
The quercetin paradox. Toxicol Appl Pharmacol (2007) 1.14
Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev Res (Phila) (2010) 1.13
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer (2005) 1.12
Postlaryngectomy voice rehabilitation: state of the art at the millennium. World J Surg (2003) 1.11
Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol (2010) 1.11
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol (2008) 1.09
Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung. Carcinogenesis (2010) 1.08
First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck (2009) 1.08
Assessment of lymphatic drainage patterns and implications for the extent of neck dissection in head and neck melanoma patients. J Surg Oncol (2011) 1.07
Role of superoxide anion on basal and stimulated nitric oxide activity in neonatal piglet pulmonary vessels. Pediatr Res (2003) 1.06
Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr (2011) 1.06
Antioxidant capacity of reaction products limits the applicability of the Trolox Equivalent Antioxidant Capacity (TEAC) assay. Food Chem Toxicol (2004) 1.06
Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke. FASEB J (2004) 1.05
Ten misconceptions about antioxidants. Trends Pharmacol Sci (2013) 1.05
In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition (2008) 1.05
Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res (2012) 1.05
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol (2007) 1.04
Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. Cancer Res (2003) 1.04
Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer (2009) 1.04
Lipoic acid: a multifunctional antioxidant. Biofactors (2003) 1.03
Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther (2008) 1.01
Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? Photodiagnosis Photodyn Ther (2009) 1.01
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
The role of DNA polymerase iota in UV mutational spectra. Mutat Res (2006) 0.99
Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol (2010) 0.99
Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. Mutat Res (2010) 0.99
Oral bioavailability of ATP after prolonged administration. Br J Nutr (2010) 0.99
Bioavailability and metabolism. Mol Aspects Med (2002) 0.99
Surgical treatment of malignant pleural mesothelioma: a review. Chest (2003) 0.99
Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem Pharmacol (2006) 0.98
Superficial parotidectomy via facelift incision. Ann Otol Rhinol Laryngol (2009) 0.98
A portable gamma-camera for intraoperative detection of sentinel nodes in the head and neck region. J Nucl Med (2010) 0.98
Transcription-dependent cytosine deamination is a novel mechanism in ultraviolet light-induced mutagenesis. Curr Biol (2009) 0.98